Spirulina Human Clinical Research: What the Evidence Shows

Spirulina Human Clinical Research: What the Evidence Shows

Spirulina is marketed as a “superfood” for cholesterol, blood sugar, weight, allergies, energy, and more. Some claims rest on real trials, and many rest on very little. This page reviews spirulina human clinical research outcome by outcome, so you can see which findings are consistent, which are preliminary, and which are mostly hype. It is written for readers who want to understand the studies themselves, not just the headlines.

Medical disclaimer: This article is educational and is not medical advice. Spirulina is a dietary supplement, not a treatment or cure for any disease. Talk to a qualified healthcare professional before using it, especially if you are pregnant, breastfeeding, have an autoimmune condition, phenylketonuria, or a chronic illness, or take prescription medicines.

1. Executive Evidence Summary

Spirulina (mainly Arthrospira platensis and A. maxima) is a cyanobacterium, often called blue-green algae, sold as tablets, capsules, and powder. The human trial literature is real but small, with short studies, mostly 1 to 10 g per day for 2 to 24 weeks.

• Lipids (most consistent signal): Several small trials and a meta-analysis report lower total cholesterol, LDL cholesterol, and triglycerides, with a modest HDL rise. Heterogeneity is high and trial quality is uneven.
• Blood pressure: Small trials and pooled analyses hint at modest reductions, mainly in people with elevated blood pressure. Evidence is limited.
• Blood glucose and type 2 diabetes: Results are mixed. Some small trials report improvements in fasting glucose or HbA1c, but the trials are few, short, and underpowered.
• Body weight and obesity: Meta-analytic evidence suggests small reductions in weight or BMI. Clinical meaningfulness is uncertain.
• Allergic rhinitis: Two small studies report symptom improvement, but the evidence is thin and the trial designs are limited.
• Exercise performance and oxidative stress: Very small studies report effects on endurance and muscle damage markers. Not enough to draw firm conclusions.
• Undernutrition, anemia, and arsenic exposure: Small trials in specific populations report improvements. Each needs larger replication.
• Safety: Pure, well-tested spirulina is generally well tolerated in trials. Contamination (microcystins, heavy metals) and rare immune-related reports are the main concerns.

Overall: Spirulina shows encouraging but low-to-moderate certainty effects on cardiometabolic markers. There is no good evidence that it prevents or treats disease, and no large, long, outcome-driven trial shows that it reduces heart attacks, diabetes complications, or mortality.

2. The Research Question

This page asks one question: in human beings, what does the published clinical evidence show about the effects of spirulina supplementation on health outcomes, and how reliable is that evidence?

It is a question about efficacy and safety in people. Laboratory and animal studies are outside scope except where they explain mechanisms. Phycocyanin, the blue pigment, and spirulina extracts are sometimes studied separately. This page focuses on whole spirulina unless otherwise stated.

3. Search and Inclusion Methodology

Important transparency note: This is a narrative evidence review, not a formal systematic review. I did not run a live database search while writing it and did not register a protocol. The studies below are widely cited, peer-reviewed human studies and reviews that I am confident exist. Citation details should be verified in PubMed before formal use.

Selection approach:

• Included: randomized controlled trials (RCTs), controlled or prospective human studies, systematic reviews, and meta-analyses of spirulina supplementation in humans.
• Prioritized: placebo-controlled and double-blind designs, and studies with clinical or biomarker endpoints.
• Excluded from the evidence grading: animal and in vitro work, unreferenced marketing claims, and studies of mixed products where spirulina’s contribution cannot be isolated.
• Not covered: an exhaustive list. Many additional small trials exist, and this page cannot guarantee that all relevant studies are included. Publication bias and selective inclusion are therefore possible.

To reproduce or extend the search, use PubMed with terms such as “spirulina” or “Arthrospira” combined with “randomized controlled trial,” and screen for human studies.

4. Spirulina Clinical Trials by Health Outcome

Cholesterol and blood lipids

This is the most studied outcome. Park et al. (2008) gave 8 g/day to elderly Koreans for 16 weeks and reported improved lipid profiles and some immune marker changes. Mazokopakis et al. (2014) reported lower cholesterol and triglycerides in a Cretan population in a prospective, non-randomized design. Ngo-Matip et al. (2015) reported improved lipid profiles in HIV-infected, antiretroviral-naïve patients.

Serban et al. (2016) pooled seven trials. They reported reductions in total cholesterol, LDL-C, and triglycerides and an increase in HDL-C. Participants and doses varied, and pooled estimates showed substantial heterogeneity. Several included trials were small, and some did not report blinding or randomization methods in detail.

Interpretation: The signal is fairly consistent in direction, but the magnitude is uncertain and probably overestimated by small-study effects.

Blood pressure

Miczke et al. (2016) ran a double-blind, placebo-controlled trial in overweight hypertensive adults using 2 g/day for 3 months. They reported improvements in blood pressure, weight, and endothelial measures. The sample was small, so the result is hypothesis-generating. Other trials report smaller or inconsistent effects, and pooled analyses suggest modest reductions, with the evidence limited by few trials.

Blood glucose and type 2 diabetes

Lee et al. (2008) studied adults with type 2 diabetes using 2 g/day for 12 weeks and reported some improvements in lipid and glycemic markers. Other small trials report reductions in fasting glucose or HbA1c, while some found little effect.

Interpretation: The data suggest possible benefit, but the trials are small and short, and spirulina is not a replacement for medical therapy. Anyone taking glucose-lowering drugs should discuss spirulina with a clinician.

Body weight and obesity

Yousefi et al. (2018) and Zeinalian et al. (2017) reported improved anthropometric measures in people with obesity or overweight, using about 2 g/day over roughly three months. Hernández-Lepe et al. (2018) combined spirulina with an exercise program, which makes it difficult to separate the effect of the supplement. Moradi et al. (2019) pooled RCTs and reported small reductions in body weight and BMI. Few trials were available, and heterogeneity was notable.

Allergic rhinitis

Mao et al. (2005) reported effects on cytokine production in allergic rhinitis patients taking a spirulina-based supplement. Cingi et al. (2008) compared spirulina with placebo in patients with allergic rhinitis and reported improvements in symptoms such as nasal discharge, sneezing, congestion, and itching. These are small studies with short follow-up, and larger replication is lacking.

Exercise performance and oxidative stress

Lu et al. (2006) and Kalafati et al. (2010) reported effects on exercise-related muscle damage or endurance measures. Both studies were very small (roughly ten participants each) and short. Results may not apply beyond recreationally trained men.

Anemia and immune function in older adults

Selmi et al. (2011) studied older adults with a history of anemia and reported improved hemoglobin and some immune parameters. The study was small and exploratory.

Undernutrition and HIV

Simporé et al. (2006) reported nutritional rehabilitation outcomes in undernourished children, and Azabji-Kenfack et al. (2011) studied malnourished HIV-infected adults. These are context-specific nutrition studies. Findings reflect spirulina as a food source and cannot be generalized to healthy adults.

Arsenic poisoning

Misbahuddin et al. (2006) reported that spirulina extract plus zinc reduced hair arsenic levels in people with chronic arsenic poisoning. Results are intriguing but come from a small trial, and independent replication is needed.

5. Human Studies Table

The table summarizes key studies. Sample sizes and regimens are approximate where marked; check the original paper for exact figures.

6. Study Design Quality

Most spirulina trials are small, short, and single-center.

Strengths: Many trials are randomized, and several are double-blind and placebo-controlled. Outcomes such as cholesterol and blood pressure are objective and measurable.

Weaknesses:

• Sample sizes are commonly under 100, and some have fewer than 15 participants.
• Randomization and blinding methods are often poorly described.
• Placebo composition varies, and the color and taste of spirulina can make blinding difficult.
• Dropout and adherence reporting is inconsistent.
• Multiple outcomes are often reported without correction, raising the risk of chance findings.
• Co-interventions (exercise, diet) complicate interpretation in some studies.
• Small-study effects: small positive trials are more likely to be published than null ones.

Overall, most trials would be rated as having some concerns or a high risk of bias on standard tools. I have not applied a formal risk-of-bias tool such as Cochrane RoB 2 here.

7. Participant Characteristics

Trial populations are diverse but narrow:

• Adults with metabolic risk: overweight or obesity, hypertension, type 2 diabetes, or dyslipidemia
• Older adults: elderly Koreans, older Italians with anemia history
• Allergic rhinitis patients
• Healthy, trained young men (exercise studies)
• Undernourished or HIV-infected populations in sub-Saharan Africa
• People with chronic arsenic exposure in South Asia

Geography includes Korea, Greece, Poland, Iran, Mexico, Turkey, Italy, Cameroon, Burkina Faso, and Bangladesh. This is a strength for diversity, but results from one region and population cannot be assumed to generalize. Children, pregnant people, and people with kidney or autoimmune disease are poorly represented.

8. Dose and Form Used

• Typical doses: 1 to 10 g per day, commonly 2 to 8 g.
• Forms: Tablets, capsules, and powder. Few studies compare forms.
• Sources: Products differ in strain, cultivation (open ponds versus controlled systems), processing, and nutrient content.
• Product consistency: Most trials do not report detailed composition, such as phycocyanin content, protein, or contaminant testing.

Dose-response evidence is limited. Few trials compare multiple doses within the same design, so the “best” dose is not established. Products and doses differ in ways that make pooling results less certain.

9. Duration of Spirulina Trials

Most trials last 4 to 24 weeks, with 8 to 12 weeks most common. Cingi et al. extended to roughly six months. There are essentially no multi-year randomized trials of spirulina.

This matters because lipid and glucose markers can change quickly, but whether benefits persist, fade, or have long-term effects on disease outcomes is unknown. Safety data are also limited by duration.

10. Primary Endpoints

Endpoints are overwhelmingly surrogate or biomarker outcomes:

• Serum lipids (total cholesterol, LDL-C, HDL-C, triglycerides)
• Blood pressure
• Fasting glucose and HbA1c
• Body weight, BMI, and body composition
• Cytokines and immune markers
• Symptom scores in allergic rhinitis
• Exercise time to exhaustion and oxidative stress markers
• Hemoglobin and nutritional status

No trial discussed here was powered to detect effects on heart attack, stroke, diabetes onset, fracture, or death. This is a central limitation: improvement in a biomarker does not guarantee improvement in health outcomes.

11. Results: What the Trials Found

Across the evidence:

• Lipids: Most trials favor spirulina over control, with effect sizes varying widely. The Serban meta-analysis supports lower LDL-C and triglycerides and a modest HDL-C increase.
• Blood pressure: Small reductions in hypertensive or overweight participants, inconsistent in normotensive people.
• Glycemia: Mixed, with some improvement in fasting glucose or HbA1c and some null results.
• Weight and BMI: Small reductions in pooled analyses, with limited trial numbers.
• Allergic rhinitis: Symptom improvement in two small studies.
• Other outcomes: Preliminary positive findings, not yet replicated at scale.

Some trials reported no significant effect on one or more outcomes, which is expected and healthy. Readers should be skeptical of any source reporting uniformly positive results.

12. Clinical Significance

Statistical significance is not clinical significance. A lipid change of a few mg/dL, a blood pressure drop of a few mmHg, or a weight change under 2 kg may not alter an individual’s risk meaningfully.

• Lipids: If the larger pooled effects were real, they would be clinically relevant, but small-study bias likely inflates them. Spirulina should not replace statins or other proven therapies when those are indicated.
• Blood pressure: Modest reductions could matter at the population level, but are not enough to replace antihypertensive treatment.
• Glucose: No evidence supports replacing diabetes medicine or monitoring with spirulina.
• Weight: Effects, if real, are small compared with diet and physical activity.
• Allergies: Symptom benefit needs confirmation before it can be recommended over standard care.

13. Conflicts of Interest and Funding

Funding and conflict-of-interest statements vary by trial. Spirulina studies are commonly funded by universities, hospitals, and public grants, but some are supported by supplement companies or use donated products. Authors may also hold ties to manufacturers.

I have not audited the disclosure statements of each study here, so I cannot make claims about specific papers. Readers should check each paper’s funding and conflict-of-interest sections. Industry involvement does not automatically invalidate a trial, but it raises the importance of independent replication, preregistration, and transparent reporting.

14. Consistency Across Spirulina Clinical Trials

Reasonably consistent: Direction of effect on LDL-C and triglycerides across several trials, although size varies.

Moderately consistent: Weight, BMI, and blood pressure, generally modest.

Inconsistent: Glycemic outcomes, where some trials show effects and others do not.

Too sparse to assess: Allergic rhinitis, exercise, anemia, arsenic, and undernutrition.

Consistency is affected by differences in dose, product, baseline health, duration, and trial quality. Heterogeneity is a recurring theme in pooled analyses, which limits confidence in pooled estimates.

15. Meta-Analyses and Systematic Reviews

• Serban et al. (2016), Clinical Nutrition: Meta-analysis of seven trials on lipids, reporting reductions in total cholesterol, LDL-C, and triglycerides and a rise in HDL-C. The authors noted heterogeneity and the small number of trials.
• Moradi et al. (2019), Complementary Therapies in Medicine: Meta-analysis of RCTs on obesity-related outcomes, reporting small reductions in body weight and BMI.
• Karkos et al. (2011), Evidence-Based Complementary and Alternative Medicine: A review of spirulina’s evidence-based human applications across multiple conditions. It is a narrative overview rather than a pooled analysis.
• Deng and Chow (2010), Cardiovascular Therapeutics: A review of hypolipidemic, antioxidant, and anti-inflammatory activities, mixing human and preclinical evidence.
• Marles et al. (2011), Critical Reviews in Food Science and Nutrition: A United States Pharmacopeia safety evaluation of spirulina.

Additional meta-analyses of spirulina on blood pressure and glycemic outcomes have been published. I have not listed them because I cannot confirm their citation details from memory. Search PubMed for current ones.

Meta-analyses of small, heterogeneous trials can amplify bias instead of removing it, so pooled results here should be treated as provisional.

16. Spirulina Evidence Grading

The grades below are my editorial judgment, loosely inspired by GRADE principles, not formal GRADE assessments.

17. Limitations of the Evidence

• Small samples and short duration limit precision and long-term inference.
• Surrogate endpoints do not prove clinical benefit.
• Heterogeneous products and doses limit comparability.
• Risk of bias is common due to unclear randomization, blinding, and reporting.
• Publication bias may favor positive studies.
• Contamination risk: Spirulina grown in uncontrolled conditions can contain microcystins from other cyanobacteria and heavy metals (Gilroy et al., 2000; Marles et al., 2011). Trials rarely report batch testing.
• Safety data are limited. Reports exist of immune activation in people with autoimmune conditions (Lee and Werth, 2004), and spirulina contains phenylalanine, which is relevant for people with phenylketonuria.
• Limited generalizability to children, pregnancy, and people with chronic disease.
• Review limitations: This page is a narrative review without a formal protocol or live database search, so it may omit relevant studies.

18. Bottom-Line Interpretation

Spirulina human clinical research suggests that spirulina may modestly improve some cardiometabolic markers, especially lipids, over weeks to months in the small trials conducted so far. For other outcomes, the evidence is too thin to support confident claims.

What can reasonably be said:

• Spirulina has been studied in humans, and some trials report favorable changes in biomarkers.
• The evidence is of low to moderate certainty at best.
• High-quality spirulina is generally well tolerated in studies, but product quality varies.

What cannot be said:

• That spirulina treats, cures, or prevents diabetes, heart disease, allergies, or any other disease.
• That it should replace prescribed medicine.
• That it is proven to improve long-term health outcomes.

Practical steps if you are considering it:

1. Discuss it with a clinician, especially if you take medicines or have an autoimmune condition, phenylketonuria, or are pregnant.
2. Choose products with independent third-party testing for heavy metals and microcystins.
3. Keep realistic expectations. Any effect is likely modest and does not replace diet, exercise, or prescribed care.
4. Track relevant measures with your clinician, such as lipids or blood pressure, rather than relying on claims.

19. References

Please verify all citation details (volume, pages, DOI) through PubMed or the publisher before formal use. No live database search was run while preparing this page, and I have deliberately not listed DOIs from memory.

1. Serban MC, Sahebkar A, Dragan S, et al. A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations. Clin Nutr. 2016;35(4):842-851.
2. Moradi S, Ziaei R, Foshati S, Mohammadi H, Nachvak SM, Rouhani MH. Effects of Spirulina supplementation on obesity: a systematic review and meta-analysis of randomized clinical trials. Complement Ther Med. 2019;47:102211.
3. Karkos PD, Leong SC, Karkos CD, Sivaji N, Assimakopoulos DA. Spirulina in clinical practice: evidence-based human applications. Evid Based Complement Alternat Med. 2011;2011:531053.
4. Deng R, Chow TJ. Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina. Cardiovasc Ther. 2010;28(4):e33-e45.
5. Marles RJ, Barrett ML, Barnes J, et al. United States Pharmacopeia safety evaluation of spirulina. Crit Rev Food Sci Nutr. 2011;51(7):593-604.
6. Park HJ, Lee YJ, Ryu HK, Kim MH, Chung HW, Kim WY. A randomized double-blind, placebo-controlled study to establish the effects of spirulina in elderly Koreans. Ann Nutr Metab. 2008;52(4):322-328.
7. Lee EH, Park JE, Choi YJ, Huh KB, Kim WY. A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patients. Nutr Res Pract. 2008;2(4):295-300.
8. Mazokopakis EE, Starakis IK, Papadomanolaki MG, Mavroeidi NG, Ganotakis ES. The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study. J Sci Food Agric. 2014;94(3):432-437.
9. Miczke A, Szulinska M, Hansdorfer-Korzon R, et al. Effects of spirulina consumption on body weight, blood pressure, and endothelial function in overweight hypertensive Caucasians: a double-blind, placebo-controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2016;20(1):150-156.
10. Zeinalian R, Farhangi MA, Shariat A, Saghafi-Asl M. The effects of Spirulina platensis on anthropometric indices, appetite, lipid profile and serum vascular endothelial growth factor (VEGF) in obese individuals: a randomized double blinded placebo controlled trial. BMC Complement Altern Med. 2017;17:225.
11. Yousefi R, Mottaghi A, Saidpour A. Spirulina platensis effectively ameliorates anthropometric measurements and obesity-related metabolic disorders in obese or overweight healthy individuals: a randomized controlled trial. Complement Ther Med. 2018;40:106-112.
12. Hernández-Lepe MA, Wall-Medrano A, López-Díaz JA, et al. Effect of Arthrospira (Spirulina) maxima supplementation and a systematic physical exercise program on the body composition and cardiorespiratory fitness of overweight or obese subjects: a double-blind, randomized, and crossover controlled trial. Mar Drugs. 2018;16(10):364.
13. Cingi C, Conk-Dalay M, Cakli H, Bal C. The effects of spirulina on allergic rhinitis. Eur Arch Otorhinolaryngol. 2008;265(10):1219-1223.
14. Mao TK, Van de Water J, Gershwin ME. Effects of a Spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. J Med Food. 2005;8(1):27-30.
15. Kalafati M, Jamurtas AZ, Nikolaidis MG, et al. Ergogenic and antioxidant effects of spirulina supplementation in humans. Med Sci Sports Exerc. 2010;42(1):142-151.
16. Lu HK, Hsieh CC, Hsu JJ, Yang YK, Chou HN. Preventive effects of Spirulina platensis on skeletal muscle damage under exercise-induced oxidative stress. Eur J Appl Physiol. 2006;98(2):220-226.
17. Selmi C, Leung PS, Fischer L, et al. The effects of Spirulina on anemia and immune function in senior citizens. Cell Mol Immunol. 2011;8(3):248-254.
18. Simpore J, Kabore F, Zongo F, et al. Nutrition rehabilitation of undernourished children utilizing Spiruline and Misola. Nutr J. 2006;5:3.
19. Azabji-Kenfack M, Dikosso SE, Loni EG, et al. Potential of Spirulina platensis as a nutritional supplement in malnourished HIV-infected adults in Sub-Saharan Africa: a randomised, single-blind study. Nutr Metab Insights. 2011;4:29-37.
20. Ngo-Matip ME, Pieme CA, Azabji-Kenfack M, et al. Effects of Spirulina platensis supplementation on lipid profile in HIV-infected antiretroviral naïve patients in Yaoundé-Cameroon: a randomized trial study. Lipids Health Dis. 2015;14:10.
21. Misbahuddin M, Islam AZ, Khandker S, Ifthaker-Al-Mahmud, Islam N, Anjumanara. Efficacy of spirulina extract plus zinc in patients of chronic arsenic poisoning: a randomized placebo-controlled study. Clin Toxicol (Phila). 2006;44(2):135-141.
22. Gilroy DJ, Kauffman KW, Hall RA, Huang X, Chu FS. Assessing potential health risks from microcystin toxins in blue-green algae dietary supplements. Environ Health Perspect. 2000;108(5):435-439.
23. Lee AN, Werth VP. Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol. 2004;140(6):723-727.

Useful starting points: PubMed (https://pubmed.ncbi.nlm.nih.gov/) for locating each record and its DOI, and the National Center for Complementary and Integrative Health (https://www.nccih.nih.gov/) for consumer-level information on blue-green algae supplements (confirm the current page address on the site).